Home › Research › Costs and economics
Changes in Out-of-Pocket Drug Expenditures Among Medicare Beneficiaries With Dementia Under the Inflation Reduction Act: A Simulation Study
Zhu Y, Olchanski N, Freund KM, Cohen JT, Neumann PJ, Lin PJ. Value in Health, 2025-01-27
Topic: Risk, prevention and care in population studies
Plain-language summary
Objectives We investigated how the Inflation Reduction Act (IRA) Medicare Part D benefit redesign may reduce out-of-pocket (OOP) drug expenditures for Medicare beneficiaries with dementia. Methods Using data from the Health and Retirement Study (HRS) linked with Medicare claims, we simulated post-redesign OOP drug spending by applying the 2025 prescription drug cost-sharing rules to each beneficiary's pre-redesign Part D medication utilization for 2016, adjusting for inflation. Our study population comprised HRS respondents aged 65 and older in 2016, enrolled in Medicare fee for service, with at least one Part D drug claim in 2016, and diagnosed with dementia between 2000 and 2016 (n = 1677). We compared pre-redesign and post-redesign annual OOP drug expenditures stratified by: (1) low-income subsidy (LIS) eligibility status; (2) household income among non-LIS beneficiaries; (3) comorbidity count, and 4) cognitive impairment severity. Results After the redesign, we project average annual OOP drug expenditures among LIS beneficiaries with dementia to decrease from $56 to $25-representing a $31, or 55%, reduction. In contrast, among non-LIS beneficiaries, average OOP drug expenditures is projected to decrease from $772 to $576, a $196, or 25% reduction. We project the reduction in OOP drug expenditures to be greater among beneficiaries with 6 to 8 comorbidities (45%) than among beneficiaries with fewer comorbidities (21%-26%). Conclusions The Inflation Reduction Act Medicare Part D benefit redesign will reduce OOP drug spending for beneficiaries with dementia, resulting in potentially marked savings not only for low-income beneficiaries and beneficiaries with a high comorbidity burden but also for higher-income beneficiaries.
What this study adds
Evidence grade: Moderate
The record lists 1,677 participants. It addresses drug cost sharing rather than treating, curing, or preventing Alzheimer's disease. Reported effect size: 25% ($196) reduction in annual out-of-pocket drug spending for non-LIS beneficiaries; 55% ($31) for LIS beneficiaries.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Zhu, Y., Olchanski, N., Freund, K. M., Cohen, J. T., Neumann, P. J., & Lin, P. J. (2025). Changes in Out-of-Pocket Drug Expenditures Among Medicare Beneficiaries With Dementia Under the Inflation Reduction Act: A Simulation Study. Value in Health. https://doi.org/10.1016/j.jval.2025.01.008
Vancouver
Zhu Y, Olchanski N, Freund KM, Cohen JT, Neumann PJ, Lin PJ. Changes in Out-of-Pocket Drug Expenditures Among Medicare Beneficiaries With Dementia Under the Inflation Reduction Act: A Simulation Study. Value in Health. 2025. doi:10.1016/j.jval.2025.01.008. PMID: 39880200.
BibTeX
@article{zhu2025-39880200,
author = {Zhu, Y. and Olchanski, N. and Freund, K. M. and Cohen, J. T. and Neumann, P. J. and Lin, P. J.},
title = {{Changes in Out-of-Pocket Drug Expenditures Among Medicare Beneficiaries With Dementia Under the Inflation Reduction Act: A Simulation Study}},
journal = {Value in Health},
year = {2025},
doi = {10.1016/j.jval.2025.01.008},
pmid = {39880200},
url = {https://doi.org/10.1016/j.jval.2025.01.008}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Results After the redesign, we project average annual OOP drug expenditures among LIS beneficiaries with dementia to decrease from $56 to $25-representing a $31, or 55%, reduction.
Why it matters
This simulation projected that under the Inflation Reduction Act Medicare Part D redesign, average annual out-of-pocket drug expenditures among beneficiaries with dementia would fall from $56 to $25 for low-income subsidy beneficiaries and from $772 to $576 for non-low-income subsidy beneficiaries. It addresses drug cost sharing rather than treating, curing, or preventing Alzheimer's disease.
New to this subject? Start with our plain-English guide: Costs & economics →
Study details
- Study designmodelling
- Participants1,677
- Effect size25% ($196) reduction in annual out-of-pocket drug spending for non-LIS beneficiaries; 55% ($31) for LIS beneficiaries
- Evidence strengthModerate
Limitations
Only the Part D benefit redesign was modelled, not other IRA provisions such as the insulin cap, vaccine cost-sharing elimination or price negotiation; effects on plan premiums or drug-access restrictions were not estimated; and drug utilisation, prices and plan coverage were assumed unchanged, so the analysis may have overestimated the reduction in out-of-pocket spending if utilisation rises.
How this study scored 46/100
Published in a peer-reviewed journal, and it is a computer model rather than new measurements. Scored zero for randomized / blinded because the record does not state it. We have no data on free to read, so that was left out: it earned 45 of the 98 points we could judge it on, which is 46 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Value in Health) |
| Journal's citation record | 2 / 4 | Value in Health: journal h-index 169 (OpenAlex, 2026-10-29) |
| Study design | 3 / 12 | A computer model rather than new measurements |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 3 / 4 | 1,677 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 1 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.3 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 1 / 6 | Cited 1.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 1 other studies in this library |
| Still being cited | 0 / 4 | Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Pei‐Jung Lin: h-index 15 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Tufts University: institution h-index 1,045 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 39880200) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 45 / 98 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 45 of the 98 points we could judge it on is 46 out of 100. |
| Total | 46 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
1 study in the alzhub library lists this one in its references.
Related studies in Costs and economics from nearby years
Also tagged “prevalence”
1,224 studies in the library carry the topic tag “prevalence”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,224 tagged studies.